Studies for AZD4547 and BGJ389 revealed that patients with FGFR1 amplification (non-small cell lung cancer) or bearing FGFR3 mutations (bladder cancer) displayed a partial response to the therapy (47, 48). Here, FGFR1 is linked to urinary bladder carcinoma.